The effect of BMP-2 on the osteoconductive properties of β-tricalcium phosphate in rat calvaria defects

Luvizuto, Eloá Rodrigues; Tangl, Stefan; Zanoni, Gerald; Okamoto, Tetuo; Sonoda, Celso Koogi; Gruber, Reinhard; Okamoto, Roberta

doi:10.1016/j.biomaterials.2011.01.076

Cited by 88 publications

(83 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These data corroborate with the results found by Luvizuto et al (2011) showing that the presence of BMP-2 decreases the osteoconductive properties of PLGA.…”

Section: Discussionsupporting

confidence: 83%

See 1 more Smart Citation

Polylactic/polyglycolic acid copolymer is a good carrier for bmp-2 on bone regeneration?

Anjos¹,

Perez²,

Braga³

et al. 2017

Biosci. J.

View full text Add to dashboard Cite

ABSTRACT:The aim of this work was to evaluate the role of polylactic /polyglycolic acid copolymer as carrier for BMP-2 on bone regeneration in rat calvarium. Forty five adult male rats underwent 5-mm critical defects in bone calvaria to be divided into three groups according to the filling materials: Control-blood clot; PLGA-polylactic acid Polyglycolic/copolymer; PLGA + BMP-2 -polylactic acid Polyglycolic/copolymer associated with BMP-2. Sacrifice of animals occurred at 5, 15 and 30 days after surgery The evaluation of new bone formation was obtained by histomorphometry, while OPG and RANKL proteins were observed by immunohistochemistry. Statistical analysis was performed by means of nonparametric tests based on quantitative variables of independent samples. Considering the amount of newly formed bone, significant difference was detected between PGLA (178,2±137,5µm) and the other groups, at day 30. In PLGA + BMP-2 and control groups, the expression of RANKL was prevalent on the OPG in the periods of 15 and 30 days, suggesting a favorable condition for bone reabsorption in these periods. Therefore, immunoexpression of RANKL and OPG and bone formation observed in different groups and periods of analysis showed that the polylactic/polyglycolic acid copolymer does not act as a good carrier for BMP-2.

show abstract

“…These data corroborate with the results found by Luvizuto et al (2011) showing that the presence of BMP-2 decreases the osteoconductive properties of PLGA.…”

Section: Discussionsupporting

confidence: 83%

“…Decreased release of BMP-2 can justify a lower control bone formation observed in this study. Luvizuto et al (2011) evaluated the influence of BMP-2 associated with the PLGA, among other biomaterials. As well as in this study, they did not observe better results when the growth factor has been associated with the PLGA.…”

Section: Discussionmentioning

confidence: 99%

Polylactic/polyglycolic acid copolymer is a good carrier for bmp-2 on bone regeneration?

Anjos¹,

Perez²,

Braga³

et al. 2017

Biosci. J.

View full text Add to dashboard Cite

show abstract

“…Even though rhBMP-2 exerts its eff ect in a dose-dependent manner, BMPs shows a therapeutic dose barrier, below which carriers do not function better with the addition of rhBMP-2 and a threshold dose above without any additional benefi ts 52,53) . Approximately, the general requirement of rhBMP-2 varied from 5 μg for mice (in muscle), 50 μg for rabbit (femur defect), 400 μg for dogs (ribs) and milligram quantities of rhBMP-2 for human (spinal fusion) 54) .…”

Section: Discussionmentioning

confidence: 99%

Demineralized Dentin Matrix as a Carrier of Recombinant Human Bone Morphogenetic Proteins: <i>in Vivo</i> Study

Kim

Jun

et al. 2018

J. Hard Tissue Biology.

View full text Add to dashboard Cite

This study aimed to evaluate the effi cacy of rabbit demineralized dentin matrix (DDM) as a recombinant human bone morphogenetic protein-2 (rhBMP-2) carrier using the subcutaneous tissues of mice and rabbit calvarial critical-sized defects. DDM of rabbit, combined with rhBMP-2 (DDM/rhBMP-2) was transplanted into the subcutaneous tissues of 6 mice and 6 rabbit calvarial critical-sized defects (DDM = 0.03 g, control; DDM/rhBMP-2 = 0.03 g of DDM, 0.2 mg/ml, 5.0 μg of rhBMP-2, experimental). Both DDM and DDM/rhBMP-2 was transplanted into the left and right subcutaneous tissues of mice symmetrically. For rabbits, 4 round critical-sized defects (8 mm diameter) were formed on the exposed skull. DDM was transplanted into the 2 defects on the left sides (n = 12) and DDM/rhBMP-2 into the right sides (n = 12). Two animals among 6 mice and 6 rabbits were sacrifi ced respectively at the 1, 2, and 4 experimental weeks for the histological and histomorphometrical evaluations with hematoxylin and eosin staining. Tissues from rabbits were imaged via micro-computed tomography (μCT). DDM/rhBMP-2 in mice induced new bone formation at 2 weeks and maturation with bone marrow at 4 weeks. DDM/rhBMP-2 in rabbit calvarium induced new bone formation remarkably at 4 weeks 21.77-47.99% compared to the DDM. These observations suggest that DDM could be considered a potential carrier of rhBMP-2. The rhBMP-2 loaded on DDM enhanced bone formation.

show abstract

“…12,32-50 (3) Bioactive factors directly dispersed, immobilized, or adsorbed into the three-dimensional construct. 3,4,[6][7][8][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67][68] The level of immobilization determines the release rate of GFs and consequently their effect on tissue formation. Several studies approach a particularly relevant immobilization method, mimicking native extracellular matrix (ECM), affinity-bound systems, through the inclusion of heparin domains on the structure, thus expecting an enhanced stability of the entrapped GF.…”

Section: Single Gf Deliverymentioning

confidence: 99%

Controlled Release Strategies for Bone, Cartilage, and Osteochondral Engineering—Part II: Challenges on the Evolution from Single to Multiple Bioactive Factor Delivery

Santo

Gomes²,

Mano³

et al. 2013

Tissue Engineering Part B: Reviews

100

View full text Add to dashboard Cite

The development of controlled release systems for the regeneration of bone, cartilage, and osteochondral interface is one of the hot topics in the field of tissue engineering and regenerative medicine. However, the majority of the developed systems consider only the release of a single growth factor, which is a limiting step for the success of the therapy. More recent studies have been focused on the design and tailoring of appropriate combinations of bioactive factors to match the desired goals regarding tissue regeneration. In fact, considering the complexity of extracellular matrix and the diversity of growth factors and cytokines involved in each biological response, it is expected that an appropriate combination of bioactive factors could lead to more successful outcomes in tissue regeneration. In this review, the evolution on the development of dual and multiple bioactive factor release systems for bone, cartilage, and osteochondral interface is overviewed, specifically the relevance of parameters such as dosage and spatiotemporal distribution of bioactive factors. A comprehensive collection of studies focused on the delivery of bioactive factors is also presented while highlighting the increasing impact of platelet-rich plasma as an autologous source of multiple growth factors.

show abstract

The effect of BMP-2 on the osteoconductive properties of β-tricalcium phosphate in rat calvaria defects

Cited by 88 publications

References 21 publications

Polylactic/polyglycolic acid copolymer is a good carrier for bmp-2 on bone regeneration?

Polylactic/polyglycolic acid copolymer is a good carrier for bmp-2 on bone regeneration?

Demineralized Dentin Matrix as a Carrier of Recombinant Human Bone Morphogenetic Proteins: <i>in Vivo</i> Study

Controlled Release Strategies for Bone, Cartilage, and Osteochondral Engineering—Part II: Challenges on the Evolution from Single to Multiple Bioactive Factor Delivery

Contact Info

Product

Resources

About